{"blog_url":"https://uneyama.hatenadiary.jp/","categories":["EFSA"],"version":"1.0","width":"100%","blog_title":"\u98df\u54c1\u5b89\u5168\u60c5\u5831blog\u904e\u53bb\u8a18\u4e8b","author_url":"https://blog.hatena.ne.jp/uneyama/","url":"https://uneyama.hatenadiary.jp/entry/20160408/p7","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Funeyama.hatenadiary.jp%2Fentry%2F20160408%2Fp7\" title=\"\u610f\u898b - \u98df\u54c1\u5b89\u5168\u60c5\u5831blog\u904e\u53bb\u8a18\u4e8b\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","description":"\u30bc\u30a2\u30e9\u30ec\u30ce\u30f3\u3068\u305d\u306e\u4ee3\u8b1d\u7269\u306e\u5065\u5eb7\u5f71\u97ff\u306b\u57fa\u3065\u304f\u30b0\u30eb\u30fc\u30d7\u6307\u6a19\u5024\u3092\u8a2d\u5b9a\u3059\u308b\u3053\u3068\u306e\u59a5\u5f53\u6027 Appropriateness to set a group health-based guidance value for zearalenone and its modified forms EFSA Journal 2016;14(4):4425 [46 pp.]. 5 April 2016 http://www.efsa.europa.eu/en/efsajournal/pub/4425 \u73fe\u5728\u306e\u30bc\u30a2\u30e9\u30ec\u30ce\u30f3(ZEN)\u306e\u8010\u5bb9\u4e00\u65e5\u6442\u53d6\u91cf(TDI)\u306f2011\u5e74\u306b\u30d5\u30fc\u30c9\u30c1\u30a7\u30fc\u30f3\u306b\u304a\u3051\u308b\u6c5a\u67d3\u7269\u8cea\u306b\u95a2\u3059\u308bEFSA\u306e\u30d1\u30cd\u2026","height":"190","published":"2016-04-08 00:00:06","provider_url":"https://hatena.blog","title":"\u610f\u898b","provider_name":"Hatena Blog","image_url":null,"type":"rich","author_name":"uneyama"}